Product Description
Bicalutamide is a type of hormone drug called an anti androgen. It stops testosterone from reaching the cancer cells. This can slow the growth of your cancer and may shrink it. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/bicalutamide)
Mechanisms of Action: AR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Netherlands, New Zealand, United States
Active Clinical Trial Count: 14
Highest Development Phases
Phase 3: Adenocarcinoma|Bone Cancer|Ovarian Cancer|Prostate Cancer
Phase 2: Breast Cancer|Male Breast Cancer|Triple Negative Breast Cancer
Phase 1: Lower Urinary Tract Symptoms|Peripheral Arterial Disease|Peripheral Vascular Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PREDICT-RT* | P3 |
Recruiting |
Prostate Cancer|Adenocarcinoma|Bone Cancer |
2033-12-31 |
|
| GUIDANCE | P3 |
Recruiting |
Adenocarcinoma|Prostate Cancer |
2032-04-30 |
|
| SPA TRIAL | P3 |
Active, not recruiting |
Prostate Cancer|Adenocarcinoma |
2029-03-16 |
|
| 2022-502272-23-00 | P2 |
Unknown Status |
Triple Negative Breast Cancer |
2027-12-01 |